[Uterine carcinosarcoma].
Uterine carcinosarcoma is a rare, metaplastic subtype of endometrial cancer comprised of two distinct malignant components - epithelial and mesenchymal, with phenotypic features. This tumor shows very aggressive behavior including both local recurrence and distant metastases. Surgery consisting of total hysterectomy bilateral salpingo-oophorectomy and dissection of pelvic and para-aortic lymph node, with detailed examination of the entire abdominopelvic cavity and maximal cytoreduction of the lesions, is the principal treatment. The optimal postoperative therapy has not been determined, and is individualized. In a randomized trial a postoperative radiotherapy was shown to improve local control but no survival benefit. High rate of distant metastases suggests a potential role of the systemic therapy However the benefit of postoperative chemotherapy in high-risk patients has not been confirmed in randomized studies. This method, in addition to palliative radiotherapy and surgery is used in recurrent and advanced disease. Currently chemotherapy including the combination of paclitaxel with ifosfamide or carboplatin is considered the most effective regimen, with the latter having a better toxicity profile.
Katedra i Klinika Onkologii i Radioterapii, Gdański Uniwersytet Medyczny, Polska. kserkies@wp.pl
Krystyna
K
Serkies
Jacek
J
Jassem
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002296:Carcinosarcoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D016019:Survival Analysis; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016387:Women's Health